» Articles » PMID: 28592183

Vaginal Film for Prevention of HIV: Using Visual and Tactile Evaluations Among Potential Users to Inform Product Design

Overview
Publisher Informa Healthcare
Specialties Pharmacology
Pharmacy
Date 2017 Jun 9
PMID 28592183
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Topical prevention of HIV and other STIs is a global health priority. To provide options for users, developers have worked to design safe, effective and acceptable vaginal dissolving film formulations. We aimed to characterize user experiences of vaginal film size, texture and color, and their role in product-elicited sensory perceptions (i.e. perceptibility), acceptability and willingness to use. In the context of a user-centered product evaluation study, we elicited users' 'first impressions' of various vaginal film formulation designs via visual and tactile prototype inspection during a qualitative user evaluation interview. Twenty-four women evaluated prototypes. Participants considered size and texture to be important for easy insertion. Color was more important following dissolution than prior to insertion. When asked to combine and balance all properties to arrive at an ideal film, previously stated priorities for individual characteristics sometimes shifted, with the salience of some individual characteristics lessening when multiple characteristics were weighted in combination. While first impressions alone may not drive product uptake, users' willingness to initially try a product is likely impacted by such impressions. Developers should consider potential users' experiences and preferences in vaginal film design. This user-focused approach is useful for characterizing user sensory perceptions and experiences relevant to early design of prevention technologies.

Citing Articles

Vaginal Sheets with Essential Oil for the Treatment of Bacterial Vaginosis: Design, Characterization and Evaluation of Efficacy and Safety.

Tomas M, Sousa L, Oliveira A, Gomes C, Palmeira-de-Oliveira A, Cavaleiro C Gels. 2023; 9(4).

PMID: 37102907 PMC: 10137747. DOI: 10.3390/gels9040293.


Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development.

Friedland B, Plagianos M, Savel C, Kallianes V, Martinez C, Begg L AIDS Behav. 2023; 27(7):2190-2204.

PMID: 36881183 PMC: 10224828. DOI: 10.1007/s10461-022-03951-8.


Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials.

Hawley I, Song M, Scheckter R, McClure T, Piper J, Chen B AIDS Res Hum Retroviruses. 2021; 38(4):313-326.

PMID: 34969254 PMC: 9048173. DOI: 10.1089/AID.2021.0077.


Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use.

Guthrie K, Rosen R, Guillen M, Ramirez J, Vargas S, Fava J AIDS Res Hum Retroviruses. 2021; 38(7):601-610.

PMID: 34544269 PMC: 9297320. DOI: 10.1089/AID.2021.0038.


Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.

Maturavongsadit P, Shrivastava R, Sykes C, Cottrell M, Montgomery S, Kashuba A Int J Pharm. 2021; 605:120844.

PMID: 34216767 PMC: 8462127. DOI: 10.1016/j.ijpharm.2021.120844.


References
1.
Morrow K, Fava J, Rosen R, Vargas S, Shaw J, Kojic E . Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses. 2013; 30(1):78-91. PMC: 3931431. DOI: 10.1089/AID.2013.0099. View

2.
Guthrie K, Dunsiger S, Vargas S, Fava J, Shaw J, Rosen R . Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. AIDS Res Hum Retroviruses. 2016; 32(10-11):1022-1030. PMC: 5067921. DOI: 10.1089/AID.2015.0275. View

3.
Buckheit Jr R, Watson K, Morrow K, Ham A . Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 2009; 85(1):142-58. PMC: 2815091. DOI: 10.1016/j.antiviral.2009.10.013. View

4.
Ham A, Rohan L, Boczar A, Yang L, Buckheit K, Buckheit Jr R . Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res. 2012; 29(7):1897-907. PMC: 4405790. DOI: 10.1007/s11095-012-0715-7. View

5.
Romano J, Manning J, Hemmerling A, McGrory E, Young Holt B . Prioritizing multipurpose prevention technology development and investments using a target product profile. Antiviral Res. 2013; 100 Suppl:S32-8. DOI: 10.1016/j.antiviral.2013.09.016. View